Advertisement

Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends

CURRENT CLINICAL CONTROVERSIES

Keywords

Gut microbiota Cancer immunotherapy Checkpoint inhibitors Anti-PD(L) 1 Anti-CTLA-4 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare regarding this article.

References

  1. 1.
    Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep. 2017;19:3.CrossRefPubMedGoogle Scholar
  2. 2.
    Alkharabsheh O, Kannarkatt P, Kannarkatt J, Karapetyan L, Laird-Fick HS, Al-Janadi A. An overview of the toxicities of checkpoint inhibitors in older patients with cancer. J Geriatr Oncol. 2018;.  https://doi.org/10.1016/j.jgo.2018.02.002.PubMedGoogle Scholar
  3. 3.
    Firwana B, Avaritt N, Shields B, et al. Do checkpoint inhibitors rely on gut microbiota to fight cancer? J Oncol Pharm Pract. 2017;.  https://doi.org/10.1177/1078155217715903.Google Scholar
  4. 4.
    Bruneau A, Baylatry M-T, Joly AC, Sokol H. Gut microbiota: what impact on colorectal carcinogenesis and treatment? Bull Cancer. 2018;105:70–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14:356–365.CrossRefPubMedGoogle Scholar
  6. 6.
    Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017;15:465–478.CrossRefPubMedGoogle Scholar
  7. 7.
    Pitt JM, Vétizou M, Gomperts Boneca I, Lepage P, Chamaillard M, Zitvogel L. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology. 2017;6:e1132137.CrossRefPubMedGoogle Scholar
  8. 8.
    Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–1084.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–1089.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–1379.CrossRefPubMedGoogle Scholar
  11. 11.
    Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer. Ann Oncol. 2018;.  https://doi.org/10.1093/annonc/mdy103.PubMedGoogle Scholar
  12. 12.
    Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.CrossRefPubMedGoogle Scholar
  13. 13.
    Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.CrossRefPubMedGoogle Scholar
  14. 14.
    Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–108.CrossRefPubMedGoogle Scholar
  15. 15.
    Vetizou M, Trinchieri G. Anti-PD1 in the wonder-gut-land. Cell Res. 2018;28:263–264.CrossRefPubMedGoogle Scholar
  16. 16.
    Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Noelle Asmar
    • 1
    • 2
  • Tony Ibrahim
    • 3
    • 4
  • Jean-François Rey
    • 1
  1. 1.Gastroenterology and Endoscopy DepartmentArnault Tzanck InstituteSaint-Laurent du VarFrance
  2. 2.Gastroenterology Department, Faculty of MedicineSaint Joseph UniversityBeirutLebanon
  3. 3.Hematology-Oncology Department, Faculty of MedicineSaint Joseph UniversityBeirutLebanon
  4. 4.Medical Oncology DepartmentGustave Roussy InstituteVillejuifFrance

Personalised recommendations